BioPharmSignal logoBioPharmSignal

Biotech News

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock (SRRK)Scholar RockCompany update

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 14, 2026-- Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the company granted inducement equity awards covering an aggregate of 51,947 shares of its common stock to twelve newly hired employees, consisting of inducement stock options to

Related news

SRRKScholar Rock2026-07-29 12:00 EST

Scholar Rock to Present at the Canaccord Genuity 46th Annual Growth Conference

SRRKScholar Rock2026-07-16 12:00 EST

Scholar Rock to Report Second Quarter 2026 Financial Results on August 6, 2026

View all latest news

Scholar Rock

Myostatin Biology Scholar Rock develops therapies that selectively modulate growth factors in their latent forms. Its lead work targets myostatin to improve muscle function while preserving related signaling pathways. Apitegromab Apitegromab is a selective inhibitor of latent myostatin under FDA review for children and adults with spinal...

Recent company news

SRRKScholar Rock2026-08-14 20:15 EST

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SRRKScholar Rock2026-08-07 20:20 EST

Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date

SRRKScholar Rock2026-08-06 11:00 EST

Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights

SRRKScholar Rock2026-07-29 12:00 EST

Scholar Rock to Present at the Canaccord Genuity 46th Annual Growth Conference

SRRKScholar Rock2026-07-20 12:00 EST

Scholar Rock Provides Update on Timing of Committee for Medicinal Products for Human Use (CHMP) Opinion for Apitegromab Marketing Authorisation Application (MAA) for Spinal Muscular Atrophy (SMA)

Stock data

Close
52.05 USD
Market cap
5.35B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States